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BEVACIZUMAB VERSUS RANIBIZUMAB FOR AGE-RELATED MACULAR
DEGENERATION (AMD): A BUDGET IMPACT ANALYSIS
Zimmermann I, Schneiders RE, Mosca M, Alexandre RF, do Nascimento Jr JM, Gadelha
CA
Ministry of Health, Brasília, DF, Brazil
OBJECTIVES: The use of intravitreal injection of vascular endothelial growth factor
inhibitors is an effective treatment for AMD and trials have showed similar clinical
effects of bevacizumab and ranibizumab. The aim of this study was to estimate the
budget impact for Brazilian Ministry of Health (MoH) recommending ranibizumab
instead of bevacizumab for AMD.METHODS:We did a deterministic budget impact
analysis, with the MoH perspective, comparing the use of ranibizumab and bevaci-
zumab for wet AMD. The target population was estimated by extrapolating epide-
miologic data to the Brazilian population. Data about dosage, administration and
fractioning were extracted from literature. Prices were obtained with the Brazilian
regulatory agency, applying potential discounting benefits. This analysis did not
consider the cost of the fractioning process because it will be assumed by the states
and not by the MoH. RESULTS: The considered price of the ranibizumab vial was
US$ 962.86 (fractioning is not an option). In contrast, a 4 mL vial of bevacizumab
would cost US$ 410.86 (US$ 5.14 each 0.05 mL dose, resulting in 80 doses/vial).
Therefore, the expenses of one year on ranibizumab would be about US$ 11,554.37
and about US$ 61.63 for bevacizumab (12 injections for both). Thus, the use of
ranibizumab instead of bevacizumab for treating 467,600 people would be related
with a US$ 5,374,007,960.48 budget impact. The sensitivity analyses also demon-
strated a budget impact of US$ 3,097,416,007.65 and US$ 5,287,555,101.51 (1 dose/
vial and 20 doses/vial, respectively). CONCLUSIONS: Although not a label indica-
tion, bevacizumab has been widely adopted in clinical practice. As presented
above, even with inefficient fractioning methods, the use of bevacizumab would
bring substantial savings to MoH resources. Even the need of preserving the steril-
ity of the solution being a real-world worry, stability studies have showed the
maintenance of the solution characteristics through adequate handling and stor-
age.
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COST-OF-ILLNESS OF CHRONIC LYMPHOEDEMA PATIENTS IN HAMBURG AND
SUBURBAN REGION
Purwins S1, Dietz D1, Blome C2, Heyer K1, Herberger K1, Augustin M1
1University Clinics of Hamburg, Hamburg, Germany, 2University Medical Center Hamburg,
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OBJECTIVES: Chronic lymphedema is of particular interest from the socioeco-
nomic point of view, since it is accompanied with high costs, disease burden and
permanent need of medical treatment. The economic and social impact can in-
crease if complications such as erysipelas and ulcers develop. Therefore, cost-of-
illness of patients with lymphoedema or lipoedema should be known. METHODS:
Patients with chronic primary or secondary lymph- or lipoedema of upper or lower
limbs, with at most 6 months of disease duration, were enrolled in an observa-
tional, cross-sectional study in Hamburg and surroundings (population of approx-
imately 4 Mio inhabitants, 90% of which are insured in the statutory health insur-
ance (SHI) and 10% in private insurance). Standardized clinical examinations and
patient interviews were carried out. The oedemas were documented via digital
photography as well as further available patient data. Resource utilizations were
collected. From the societal perspective direct medical, non - medical and indirect
costs were computed. RESULTS: A total of 348 patients were enrolled and inter-
viewed. 90.8% of them were female and had a mean age of 57.3 14.5 years. Mean
annual costs per lymphoedema were €8121. These costs consisted of 58% direct
(€4708) and 42% indirect (€3413) costs. The SHI accounted for about €5552 expenses
and the patient €494.20 out-of-pocket costs. Conducted subgroup analyses on (a)
arm vs leg oedema and (b) primary vs secondary vs lipo-lymphoedema did not
show significant differences in costs. The main costs drivers in this study were
medical treatment and disability costs. CONCLUSIONS: The treatment of patients
with chronic lymphoedema is associated with high direct and indirect costs.
PSS7
C-REALITY (CANADIAN BURDEN OF DIABETIC MACULAR EDEMA
OBSERVATIONAL STUDY): 6-MONTH FINDINGS
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OBJECTIVES:To characterize the economic and societal burden of Diabetic Macular
Edema (DME) in Canada. METHODS: Patients with clinically significant macular
edema (CSME) were enrolled by ophthalmologists and retinal specialists across
Canada. Patients were followed over a 6-month period to combine prospective data
collected during monthly telephone interviews and at sites at months 0, 3 and 6.
Visual acuity (VA) was measured and DME-related health care resource informa-
tion was collected. Patient health-related quality of life (HRQOL) was measured
using the National Eye Institute Visual Functioning Questionnaire (VFQ-25), and
the EuroQol Five Dimensions (EQ-5D). RESULTS: A total of 145 patients [mean age
63.7 years (range: 30-86 yrs); 52% male; 81% Type 2 diabetes; mean duration of
diabetes 18 years (range: 1-62 yrs); 72% bilateral CSME] were enrolled from 16 sites
across 6 provinces in Canada. At baseline, the mean VA was 20/60 (range: 20/20-
20/800) across all eyes diagnosed with CSME (249 eyes). Sixty-three percent of pa-
tients had VA severity in the eye diagnosed with DME (worse seeing eye if both eyes
diagnosed) of normal/mild vision loss (VA 20/10 to  20/80), 10% moderate vision
loss (VA 20/80 to 20/200), and 26% severe vision loss/nearly blind (VA 20/200).
At month 6, the mean VFQ-25 composite score was 79.6, the mean EQ-5D utility
score was 0.78, and the EQ visual analogue scale (VAS) score was 71.0. The average
6-month DME-related cost per patient was $2,092 across all patients (95% confi-
dence interval: $1,694 to $2,490). The cost was $1,776 for patients with normal/mild
vision loss, $1,845 for patients with moderate vision loss, and $3,007 for patients
with severe vision loss/nearly blind. CONCLUSIONS: DME is associated with limi-
tations in functional ability and quality of life. In addition, the DME-related cost is
substantial to the Canadian health care system.
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NON-INTERVENTIONAL STUDY ON THE BURDEN OF ILLNESS IN DIABETIC
MACULAR EDEMA (DME) IN BELGIUM
Nivelle E1, Caekelbergh K1, Moeremans K1, Gerlier L2, Drieskens S3, Van dijck P4
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OBJECTIVES: To study real-life patient characteristics, treatment patterns and
costs associated with DME and visual acuity (VA) level. METHODS: The study
aimed to recruit 100 patients distributed evenly over 4 categories defined by last
measured VA. 1-year retrospective data were collected from medical records. An-
nual direct costs were calculated from resource use in medical records and official
unit costs (€ 2011). Self-reported economic burden was collected via Short Form
Health and Labour Questionnaire (SF-HLQ). Indirect costs (€ 2011) included per-
sonal expenses and caregiver burden (SF-HLQ). RESULTS: Thirteen Belgian oph-
thalmologists recruited 32, 12, 14 and 6 DME patients for VA categories 20/50,
20/63-20/160, 20/200-20/400 and 20/400 respectively. VA was stable during the
study in 86% of patients. Recruitment for lower VA categories was difficult due to
long-term vision conservation with current treatments, lack of differentiation be-
tween lowest categories in medical records and discontinuation of ophthalmolo-
gist care in lowest categories. 75% of patients had bilateral DME. 68% were treated
for DME during the study, of which 60% in both eyes. 50% received photocoagula-
tion, 33% intravitreal drugs. Less than 4% of patients had paid work; 17% received
disability replacement income. Total direct medical costs in patients receiving
active treatment ranged from €960 (lowest VA) to €3,058. 59% of direct costs were
due to monitoring and vision support, 39% to DME treatment. Indirect cost trends
were less intuitive due to small samples and large variations. Annual costs grouped
by 2 highest and 2 lowest VA levels, were respectively €114 and €312 for visual aids,
€407 and €3,854 for home care. CONCLUSIONS: The majority of DME patients had
bilateral disease. Except for the lowest VA, direct medical costs increased with VA
decrease. Indirect costs were substantially higher at lower VA levels. Low sample
sizes in some categories did not allow statistical analysis of cost differences.
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OBJECTIVES: To measure the burden of the disease and provide a basis for the
health care policy decisions. METHODS: The analysis was performed based on the
several data sources. Data on prevalence of bilateral blindness and visual impair-
ment were obtained from the official Annual Report on the Ophthalmic Clinics
Activities. Cost analysis was performed from the Health and Social Insurance per-
spective and reflects the real costs of health care payers in 2010. Information on
health care and social expenditure were obtained from State Health and Social
Insurance Funds. As detailed data on expenditures were not always available in a
necessary structure, the missing data were collected in the retrospective patient
survey. Both direct and indirect costs were evaluated and divided by the cost type
and level of visual impairment. For the estimation of indirect costs Capital method
was used. Patient survey was conducted on randomly collected geographically
homogeneous sample of 89 respondents from all over Slovakia. RESULTS:A total of
17 201 persons with bilateral blindness or visual impairment were identified in
2010. Total yearly expenditures were 63 677 300 €. Direct costs counted only for 7%
(4 468 112 €) of total costs and the most of them were caused by hospitalisations (4
001 539 €) and medical devices (307 739 €). The indirect costs counted for 59 209 188
€. The highest share represented loss of productivity (69%), followed by disability
pensions (17%) and compensation of medical devices (14%). CONCLUSIONS: The
evidence of cost-effectiveness must be demonstrated in order to get reimburse-
ment in Slovakia. According the Slovak guidelines indirect costs are accepted only
in exceptional cases. Indirect costs of blindness and visual impairment count more
than two thirds of total costs and therefore should be considered in health care
policy evaluations.
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ECONOMICAL BURDEN OF SEVERE VISUAL IMPAIRMENT AND BLINDNESS – A
SYSTEMATIC REVIEW
Köberlein J1, Beifus K1, Finger R2
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OBJECTIVES: Visual impairment and blindness pose a significant burden in terms
of costs on the affected individual as well as society. In addition to a significant loss
of quality of life associated with these impairments, a loss of independence leading
to increased dependence on caretakers and inability to engage in income generat-
ing activities add to the overall societal cost. As there are currently next to no data
capturing this impact available for Germany we conducted a systematic review of
the literature to estimate the costs of visual impairment and blindness for Ger-
many and close this gap. METHODS: A systematic literature search of the main
medical and economic information databases was conducted from January-April
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